Study summary

Hair loss returned for most people who stopped baricitinib

BRAVE-AA1 withdrawal study · Randomized withdrawal, phase 3 · Published October 2024, JAMA Dermatology

80%lost benefit after stopping, vs 7% who continued

What was tested

People whose hair regrew on baricitinib were switched to placebo or kept on the drug, and those who relapsed were retreated.

What they found

80% of those switched to placebo lost their regrowth by week 152, vs 7% who continued.
Most who restarted regained it (63% to 87.5%).

What it means

JAK pills generally need to be continued long term.

JAMA Dermatol, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.